Active, not recruitingPhase 2
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Key facts
- Who runs it
- Bluefin Biomedicine Inc.
- Where
- Bulgaria, Czechia, Germany, Poland, and Spain31 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 123 people, planned
- Started
- 27 Apr 2026
- Expected to end
- 1 Aug 2027
- Type of study
- Interventional
- Record updated
- 21 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year
- Have moderate to severe disease not well controlled by systemic antibiotic treatment
- Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study
Who cannot take part
- Recently used medications that could interfere with the study
- Have certain infections or other immune conditions
- Are pregnant or breastfeeding
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of BFB759 in adult male and female participants with HS as assessed by the count of abscesses and inflammatory nodules (AN).
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)
- Record updated
- 21 October 2026